In summary, our findings suggested that post-diagnosis Hb changes, regardless of the baseline Hb levels and the direction of changes, associate with the overall survival of the patients of various cancers and should be taken into consideration in the tailored correction of anemia treatment. The gene discussed is GSTM1; the disease is anemia (phenotype).